Keurig Dr Pepper’s KDP acquisition of JDE Peet’s is emerging as an important pillar of its growth strategy. The company closed the transaction in early April 2026 and has moved quickly on integration, including establishing an integrated U.S. sales force and unified commercial programs. Initial cost synergies also began flowing through in the second quarter, while KDP continued preparing its coffee operations for the planned separation in early 2027.
JDE Peet’s delivered $2.8 billion in net sales and $414 million in operating income in the second quarter, with profitability exceeding KDP’s expectations. Favorable pricing relative to cost inflation and productivity savings supported results, although timing benefits also provided a boost. KDP expects healthy performance over the balance of 2026 as synergies build, but management cautioned that second-quarter operating profit will likely represent the segment’s quarterly high for the year.
Integration could provide another avenue for JDE Peet’s to become a stronger growth contributor. KDP sees U.S. revenue-synergy opportunities through coordinated promotions, cross-portfolio marketing, new coffee formats and cold coffee. The companies have already moved to an integrated sales force and single invoice, while the upcoming Keurig Alta platform is expected to offer both Keurig and Peet’s consumables. These initiatives could broaden the combined coffee portfolio and strengthen commercial execution.
Meanwhile, KDP remains confident in its $400 million cost-synergy program, with opportunities spanning procurement, IT, SG&A, manufacturing and logistics. Benefits were modest in the second quarter but are expected to build in the second half and beyond. Successful execution could make JDE Peet’s an increasingly meaningful contributor to KDP, though commodity volatility, integration execution and the upcoming corporate separation remain factors to watch.
Keurig Dr Pepper’s Zacks Rank & Share Price Performance
Shares of this Zacks Rank #3 (Hold) company have gained 1.6% in the past three months, outperforming both the industry and the broader Consumer Staples sector, which have lost 1.3% and 0.6%, respectively.
KDP Stock's Past Three-Month Performance
Image Source: Zacks Investment Research
Is KDP a Value Play Stock?
Keurig Dr Pepper currently trades at a forward 12-month P/E ratio of 12.10X, lower than the industry average of 19X and the sector average of 16.81X. This valuation positions the stock at a modest discount relative to both its direct peers and the broader consumer staples sector.
The Zacks Consensus Estimate for Darling Ingredients' current financial-year sales indicates growth of 12.7% from the prior-year level. DAR delivered a trailing four-quarter earnings surprise of 38.9%, on average.
The Coca-Cola CompanyKO is a leading beverage company with a portfolio of 32 billion-dollar brands spanning sparkling beverages, water, sports drinks, dairy and value-added beverages. KO currently carries a Zacks Rank #2 (Buy).
  Â
The Zacks Consensus Estimate for Coca-Cola’s current fiscal-year sales and earnings implies growth of 4.03% and 9.7%, respectively, from the year-ago reported figures. Coca-Cola delivered a trailing four-quarter earnings surprise of 4.6%, on average.
Primo Brands CorporationPRMB is a leading North American branded beverage company focused on healthy hydration. It currently has a Zacks Rank #2.
The Zacks Consensus Estimate for Primo Brands’ current fiscal-year sales indicates growth of 2.5% from the prior year’s reported levels. PRMB delivered a trailing four-quarter earnings surprise of 7.7%, on average.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.